Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.

BACKGROUND AND OBJECTIVES The prognostic value of preformed donor-specific HLA antibodies (DSA), which are only detectable by sensitive methods, remains controversial for kidney transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The outcome of 4233 consecutive kidney transplants performed between 2012 and 2015 in 18 German transplant centers was evaluated. Most centers used a stepwise pretransplant antibody screening with bead array tests and differentiation of positive samples by single antigen assays. Using these screening results, DSA against HLA-A, -B, -C, -DRB1 and -DQB1 were determined. Data on clinical outcome and possible covariates were collected retrospectively. RESULTS Pretransplant DSA were associated with lower overall graft survival, with a hazard ratio of 2.53 for living donation (95% confidence interval [95% CI], 1.49 to 4.29; P<0.001) and 1.59 for deceased donation (95% CI, 1.21 to 2.11; P=0.001). ABO-incompatible transplantation was associated with worse graft survival (hazard ratio, 2.09; 95% CI, 1.33 to 3.27; P=0.001) independent from DSA. There was no difference between DSA against class 1, class 2, or both. Stratification into DSA <3000 medium fluorescence intensity (MFI) and DSA ≥3000 MFI resulted in overlapping survival curves. Therefore, separate analyses were performed for 3-month and long-term graft survival. Although DSA <3000 MFI tended to be associated with both lower 3-month and long-term transplant survival in deceased donation, DSA ≥3000 MFI were only associated with worse long-term transplant survival in deceased donation. In living donation, only strong DSA were associated with reduced graft survival in the first 3 months, but both weak and strong DSA were associated with reduced long-term graft survival. A higher incidence of antibody-mediated rejection within 6 months was only associated with DSA ≥3000 MFI. CONCLUSIONS Preformed DSA were associated with an increased risk for graft loss in kidney transplantation, which was greater in living than in deceased donation. Even weak DSA <3000 MFI were associated with worse graft survival. This association was stronger in living than deceased donation.

[1]  D. Roelen,et al.  Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts , 2020, Journal of transplantation.

[2]  S. Jordan,et al.  Clinical and Public Policy Implications of Pre-Formed DSA and Transplant Outcomes. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[3]  J. Jung,et al.  Impact of pretransplant donor‐specific antibodies on kidney allograft recipients with negative flow cytometry cross‐matches , 2018, Clinical transplantation.

[4]  M. Schoenberg,et al.  Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months , 2018, PloS one.

[5]  M. Bots,et al.  Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  S. Hariharan,et al.  Anti-CD20 Blocker Rituximab in Kidney Transplantation , 2018, Transplantation.

[7]  S. Jordan,et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. , 2017, The New England journal of medicine.

[8]  N. Goto,et al.  Favorable results in ABO‐incompatible renal transplantation without B cell‐targeted therapy: Advantages and disadvantages of rituximab pretreatment , 2017, Clinical transplantation.

[9]  M. Stegall,et al.  Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates , 2017, Transplantation.

[10]  C. Nast,et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation , 2017, The New England journal of medicine.

[11]  Ji Hyun Yu,et al.  Clinical outcomes of ABO‐ and HLA‐incompatible kidney transplantation: a nationwide cohort study , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  I. König,et al.  Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  X. Jouven,et al.  Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. , 2017, Journal of the American Society of Nephrology : JASN.

[14]  D. Dimova,et al.  One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  W. Arns,et al.  Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics. , 2015, Tissue antigens.

[16]  E J Steenbergen,et al.  Rituximab as Induction Therapy After Renal Transplantation: A Randomized, Double‐Blind, Placebo‐Controlled Study of Efficacy and Safety , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Martin Zeier,et al.  Three-Year Outcomes Following 1420 ABO-Incompatible Living-Donor Kidney Transplants Performed After ABO Antibody Reduction: Results From 101 Centers , 2015, Transplantation.

[18]  M. Stegall,et al.  Quantifying the Risk of Incompatible Kidney Transplantation: A Multicenter Study , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[20]  R. Montgomery,et al.  Rituximab Prevents an Anamnestic Response in Patients With Cryptic Sensitization to HLA , 2013, Transplantation.

[21]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[22]  L. Ratner,et al.  Donor-specific antibodies adversely affect kidney allograft outcomes. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  Nathan T. James,et al.  Outcomes of ABO-Incompatible Kidney Transplantation in the United States , 2012, Transplantation.

[24]  M. Mihatsch,et al.  Efficacy of Induction Therapy with ATG and Intravenous Immunoglobulins in Patients with Low‐Level Donor‐Specific HLA‐Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  Douglas E Schaubel,et al.  A Comprehensive Risk Quantification Score for Deceased Donor Kidneys: The Kidney Donor Risk Index , 2009, Transplantation.

[26]  A. Webster,et al.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data , 2005, BMJ : British Medical Journal.

[27]  P. Terasaki,et al.  Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.